About E3 ubiquitin-protein ligase pellino homolog 1
E3 ubiquitin-protein ligase pellino homolog 1 (PELI1) is a protein
from Homo sapiens identified by UniProt accession
Q96FA3, 418 residues long.
MolForge cross-references it against 0 known binders and
150 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase pellino homolog 1 |
| UniProt accession | Q96FA3 |
| Gene | PELI1 |
| Organism | Homo sapiens |
| Length | 418 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (150)
Diseases linked to this target (Open Targets).
- neuroticism measurement · score 0.32
- body height · score 0.25
- mathematical ability · score 0.23
- self reported educational attainment · score 0.23
- intelligence · score 0.14
- drug use measurement · score 0.13
- neoplasm · score 0.10
- breast adenocarcinoma · score 0.10
- Sepsis · score 0.09
- Systemic lupus erythematosus · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96FA3-F1 | alphafold | PREDICTED | 89.52 | — |
Amino-acid sequence (418 residues)
MFSPDQENHP SKAPVKYGEL IVLGYNGSLP NGDRGRRKSR FALFKRPKAN GVKPSTVHIA CTPQAAKAIS NKDQHSISYT LSRAQTVVVE YTHDSNTDMF QIGRSTESPI DFVVTDTVPG SQSNSDTQSV QSTISRFACR IICERNPPFT ARIYAAGFDS SKNIFLGEKA AKWKTSDGQM DGLTTNGVLV MHPRNGFTED SKPGIWREIS VCGNVFSLRE TRSAQQRGKM VEIETNQLQD GSLIDLCGAT LLWRTAEGLS HTPTVKHLEA LRQEINAARP QCPVGFNTLA FPSMKRKDVV DEKQPWVYLN CGHVHGYHNW GNKEERDGKD RECPMCRSVG PYVPLWLGCE AGFYVDAGPP THAFSPCGHV CSEKTTAYWS QIPLPHGTHT FHAACPFCAH QLAGEQGYIR LIFQGPLD
Explore E3 ubiquitin-protein ligase pellino homolog 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets